Eli Lilly boosts 2025 forecast as obesity and Alzheimer’s drugs show promise
Eli Lilly has raised its financial outlook for 2025, projecting revenues between $63 billion and $63.5 billion. The company also increased its earnings per share (EPS) forecast to a range of $21.80 to $22.50. This follows strong progress in its obesity and Alzheimer’s treatment pipelines, reinforcing its position in the pharmaceutical market.
The company’s latest anti-obesity drug, retatrutide, has delivered impressive results in clinical trials. A phase 3 study showed an average weight reduction of 28.7%, outperforming the leading drug tirzepatide. Lilly expects retatrutide to offer faster and more significant weight loss, particularly for patients with high BMI or obesity-related health issues.
Eli Lilly’s updated financial guidance and pipeline advancements highlight its expanding influence in obesity and Alzheimer’s treatments. With retatrutide poised to redefine weight-loss therapy and Kisunla entering new markets, the company is positioning itself for sustained growth in the coming years. The FDA’s review of orforglipron will further determine Lilly’s trajectory in the oral obesity medication space.
